PANNA

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200mg in pregnant women living with HIV

29 Dec, 2020

Authors: Vera E. Bukkems, Teun M. Post, Angela P. Colbers, David M. Burger, Elin M. Svensson Published in: American Society for Clinical Pharmacology and Therapeutics   Abstract: Once‐daily two 600mg tablets…
Read More

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

07 Sep, 2020

Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network Published in: Clin infect Dis. 2020;26.ciaa006…
Read More

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study

07 Sep, 2020

Authors: Bukkems V, Necsoi C, Hidalgo Tenorio C, et al. PANNA Network Published in: Clin infect Dis. 2020; 24;ciaa488. Abstract This phase-IV study investigated the influence of pregnancy on the pharmacokinetics…
Read More

Dolutegravir pharmacokinetics during pregnancy and postpartum

30 Aug, 2019

Authors: Colbers A, Bollen P, Freriksen J, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C, Moltó J, Taylor G, Alejandre I,  van Crevel R, Burger D; on behalf of the PANNA…
Read More

Dolutegravir pharmacokinetics during pregnancy and postpartum

30 Aug, 2019

Authors: Colbers A, Bollen P, Freriksen J, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C, Moltó J, Taylor G, Alejandre I,  van Crevel R, Burger D. Published: Oral presentation at 9th…
Read More

Efavirenz pharmacokinetics during pregnancy and infant washout

30 Aug, 2019

Authors: Kreitchmann R, Schalkwijk S, Best B, et al. Published in: Antivir Ther. 2019;24(2):95-103 Background Limited data exist on efavirenz pharmacokinetics in HIV-positive pregnant women and neonatal washout. Methods HIV-infected pregnant women receiving…
Read More

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

30 Aug, 2019

Authors: Schalkwijk S, Ter Heine R, Colbers A, et al. Published in: J Antimicrob Chemother. 2019;30 [Epub ahead of print] Background Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily…
Read More

First report of dolutegravir unbond plasma concentrations during pregnancy in HIV-positive women

30 Aug, 2018

Authors: Bollen P, Colbers A, Schalkwijk S, Velthoven-Graafland K, Konopnicki D, Weizsacker K, Hidalgo Tenorio C, van Crevel R, Burger D, on behalf of the PANNA network Published: Oral presentation…
Read More

Elvitegravir pharmacokinetics during pregnancy and postpartum

30 Aug, 2018

Authors: Colbers A, Schalkwijk S, Konopnicki D, Rockstroh  J, Burger D, on behalf of the PANNA network Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology…
Read More

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women

15 Oct, 2017

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. Published in: Clin Infect Dis. 2017; 65(8):1335-1341. Background The use of antiretroviral therapy during pregnancy is important for control of maternal…
Read More

Substantially lower rilpivirine plasma concentrations during pregnancy

30 Aug, 2017

Authors: Colbers A, Schalkwijk S, Konopnicki D, Gingelmaier A, Lambert J, van der Ende I, Moltó J, Burger D. Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th –…
Read More

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy

30 Dec, 2016

Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team. Published in: Clin Pharmacokinet. 2016;55(3):381-96 Abstract Pregnant women are usually excluded from clinical trials.…
Read More

Is pregnancy a barrier to the proposed lower dose of efavirenz?

30 Aug, 2016

Authors: Schalkwijk S, ter Heine R, Colbers A,  Huitema A, Denti P, Dooley K, Capparelli E, Best B, Cressey T, Greupink R, Russel F, Mirochnick M, Burger D. Published: 17th…
Read More

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early

30 Aug, 2016

Authors: Colbers A, Schalkwijk S, Konopnicki D, Hawkins D, Hidalgo Tenorio C, Moltò J, Taylor G, Weizsacker K, van der Ende M, Burger D Published: Oral presentation at 17th edition…
Read More

A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum

30 Aug, 2016

Authors: Schalkwijk S, Best B, Colbers A, SteK A, Wang  J, Hawkins D, Mirochnick M, Burger D; for the The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1026s Protocol…
Read More

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

04 Aug, 2016

Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al. Published in: Front Pharmacol. 2016 Aug 4;7:239. Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. Methods: IMPAACT…
Read More

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

31 Jul, 2016

Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al. Published in: AIDS. 2016; 30(12):1999-2001. No Abstract available
Read More

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women

15 May, 2016

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. For PANNA network Published in: AIDS. 2016;30(8):1239-44. Objective To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and…
Read More
1 2